Thromb Haemost 1979; 41(02): 291-295
DOI: 10.1055/s-0038-1646648
Original Articles
Schattauer GmbH Stuttgart

Factor VIII Inhibitor and Bronchogenic Carcinoma

S A D Al-Ismail
*   The Department of Haematology, Welsh National School of Medicine, University Hospital of Wales, Heath Park, Cardiff, CF4 4XW, UK
,
D H Parry
*   The Department of Haematology, Welsh National School of Medicine, University Hospital of Wales, Heath Park, Cardiff, CF4 4XW, UK
,
C U Moisey
**   The Department of Surgery, Welsh National School of Medicine, University Hospital of Wales, Heath Park, Cardiff, CF4 4XW, UK
,
A L Bloom
*   The Department of Haematology, Welsh National School of Medicine, University Hospital of Wales, Heath Park, Cardiff, CF4 4XW, UK
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 17. Februar 1978

Accepted 21. April 1978

Publikationsdatum:
09. Juli 2018 (online)

Preview

Summary

An inhibitor to procoagulant factor VIII (FVIIIC) developed in a patient three years after palliative resection of a bronchogenic carcinoma. The inhibitor was not active against ristocetin cofactor but possibly had some activity against factor XI. It responded to immunosuppressive therapy. This is apparently the first reported association of carcinoma and factor VIII inhibitor.